Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Emergent BioSolutions Inc. Common Stock (NY:EBS)

11.03 +0.11 (+1.01%)
Official Closing Price Updated: 7:00 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Watch These 4 Overbought Stocks As Market Rotation Continues
Recent market rotations and sector-specific outflows have created a ripe environment for potential pullbacks despite the market's 17% YTD gain. 
Via MarketBeat
Topics ETFs
News headline image
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports First Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors 
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Inc. (NYSE: EBS) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
News headline image
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.